Merck KGaA (MRK) Earns “Neutral” Rating from Deutsche Bank

Deutsche Bank reiterated their neutral rating on shares of Merck KGaA (FRA:MRK) in a report issued on Friday, March 9th.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase set a €95.00 ($117.28) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday, February 26th. Warburg Research set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, March 7th. Sanford C. Bernstein set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, November 29th. UBS set a €120.00 ($148.15) target price on shares of Merck KGaA and gave the company a buy rating in a report on Thursday, November 9th. Finally, Bank of America set a €95.00 ($117.28) target price on shares of Merck KGaA and gave the company a neutral rating in a report on Wednesday, December 6th. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of €100.55 ($124.13).

How to Become a New Pot Stock Millionaire

FRA MRK remained flat at $€77.90 ($96.17) on Friday. Merck KGaA has a 12 month low of €76.60 ($94.57) and a 12 month high of €115.00 ($141.98).

TRADEMARK VIOLATION NOTICE: “Merck KGaA (MRK) Earns “Neutral” Rating from Deutsche Bank” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theenterpriseleader.com/2018/04/02/merck-kgaa-mrk-given-neutral-rating-at-deutsche-bank.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply